The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid
Open accessAbstract
Misfolded alpha-synuclein (αSyn) aggregates are a hallmark event in Parkinson’s disease (PD) and other synucleinopathies. Recently, αSyn seed amplification assays (αSyn-SAAs) have shown promise as a test for biochemical diagnosis of synucleinopathies. αSyn-SAAs use the intrinsic self-replicative nature of misfolded αSyn aggregates (seeds) to multiply them in vitro. In these assays, αSyn seeds circulating in biological fluids are amplified by a cyclical process that includes aggregate fragmentation into smaller self-propagating seeds, followed by elongation at the expense of recombinant αSyn (rec-αSyn). Amplification of the seeds allows detection by fluorescent dyes specific for amyloids, such as thioflavin T. Several αSyn-SAA reports have been published in the past under the names ‘protein misfolding cyclic amplification’ (αSyn-PMCA) and ‘real-time quaking-induced conversion’. Here, we describe a protocol for αSyn-SAA, originally reported as αSyn-PMCA, which allows detection of αSyn aggregates in cerebrospinal fluid samples from patients affected by PD, dementia with Lewy bodies or multiple-system atrophy (MSA). Moreover, this αSyn-SAA can differentiate αSyn aggregates from patients with PD versus those from patients with MSA, even in retrospective samples from patients with pure autonomic failure who later developed PD or MSA. We also describe modifications to the original protocol introduced to develop an optimized version of the assay. The optimized version shortens the assay length, decreases the amount of rec-αSyn required and reduces the number of inconclusive results. The protocol has a hands-on time of ~2 h per 96-well plate and can be performed by personnel trained to perform basic experiments with specimens of human origin. The amplification of misfolded alpha-synuclein aggregates in vitro can be used for the detection, via fluorescent dyes, of pathologic amyloids in cerebrospinal fluid samples from patients affected by Parkinson’s disease, dementia with Lewy bodies or multiple-system atrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180
Self-citationCSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673
Alpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Alpha‐Synuclein as a Biomarker for Parkinson's Disease
Atik, A., Stewart, T., & Zhang, J. (2016) · Brain Pathology · doi:10.1111/bpa.12370 · Cited by 311
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Singer, W., Schmeichel, A. M., Shahnawaz, M., Schmelzer, J. D., Sletten, D. M., Gehrking, T. L., Gehrking, J. A., Olson, A. D., Suarez, M. D., Misra, P. P., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26089 · Cited by 102
Self-citation
Cited by
Siderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., Nguyen, H., Alcalay, R. N., Chahine, L. M., Foroud, T., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00109-6 · Cited by 719
Self-citationSimuni, T., Chahine, L. M., Poston, K., Brumm, M., Buracchio, T., Campbell, M., Chowdhury, S., Coffey, C., Concha-Marambio, L., Dam, T., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00405-2 · Cited by 629
Self-citationA biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria
Höglinger, G. U., Adler, C. H., Berg, D., Klein, C., Outeiro, T. F., Poewe, W., Postuma, R., Stoessl, A. J., & Lang, A. E. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00404-0 · Cited by 549
Ramesh, S., & Arachchige, A. S. P. M. (2023) · AIMS Neuroscience · doi:10.3934/neuroscience.2023017 · Cited by 289
The gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Oliver, P. J., Civitelli, L., & Hu, M. T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13138-5 · Cited by 42
“The low levels of α-synuclein isolated from gastrointestinal biopsies could be improved by using ultra-sensitive techniques like seed amplification assay (SAA) that amplifies aggregated α-synuclein [68–70].”
Metadata
- Authors
- Concha-Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M., & Soto, C.
- Venue
- Nature Protocols
- Published
- 2023-01-18
- Volume
- 18
- Issue
- 4
- Pages
- 1179-1196
- ISSN
- 1750-2799 (ISSN-L)
- 1754-2189
- OpenAlex
- W4317242213
- Cited by
- 240
- References
- 7
- FWCI
- 35.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. https://app.cochat.ai/papers/10.1038/s41596-022-00787-3
- The paper
- Concha-Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M., & Soto, C. (2023). Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nature Protocols. https://doi.org/10.1038/s41596-022-00787-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.